Nitrous Oxide Emerges as Potential Rapid-Acting Treatment for Depression

Groundbreaking research suggests laughing gas could offer new hope for those battling major depression, especially when traditional antidepressants fail.

Apr. 11, 2026 at 5:40am

Got story updates? Submit your updates here. ›

A ghostly, translucent X-ray photograph of a human brain, with glowing neural pathways and structures conceptually representing the rapid mood-elevating effects of nitrous oxide on the brain's glutamate receptors.An X-ray view of the brain reveals the potential of nitrous oxide to rapidly alleviate severe depression by targeting key neural pathways.Birmingham Today

A comprehensive meta-analysis led by researchers at the University of Birmingham reveals the exciting potential of nitrous oxide, commonly known as laughing gas, as a novel treatment for major depressive disorder (MDD) and treatment-resistant depression (TRD). The study found that a single 50% concentration dose of inhaled nitrous oxide can lead to rapid and significant reductions in depressive symptoms within just 24 hours, though repeated treatments may be needed to sustain the benefits.

Why it matters

With nearly half of all depression patients experiencing limited to no benefit from standard antidepressant treatments, there is an urgent need for new therapeutic options. The discovery that nitrous oxide, a commonly used pain reliever, could provide swift mood improvements for those struggling with severe, treatment-resistant depression offers a promising new avenue for addressing this debilitating mental health challenge.

The details

The meta-analysis, published in eBioMedicine, examined data from seven clinical trials and four protocol papers that investigated the use of nitrous oxide in treating depressive disorders, including MDD, TRD, and bipolar depression. The researchers found that a single 50% concentration dose of inhaled nitrous oxide led to rapid and significant reductions in depressive symptoms within 24 hours, though the relief was not sustained for a full week. However, repeated doses over several weeks showed more lasting improvements, suggesting that multiple treatment sessions may be crucial for maintaining the clinical benefits. Researchers believe nitrous oxide's rapid mood-elevating effects are due to its ability to target glutamate receptors in the brain, similar to the fast-acting antidepressant ketamine.

  • The meta-analysis was published on April 11, 2026.
  • The researchers plan to launch the first NHS trial in the UK to evaluate the safety and acceptability of nitrous oxide as a treatment for major depression.

The players

University of Birmingham

The lead institution behind the meta-analysis and the planned NHS trial to further investigate nitrous oxide as a treatment for major depression.

Kiranpreet Gill

A PhD researcher at the University of Birmingham and the lead author of the meta-analysis study.

Steven Marwaha

A professor at the University of Birmingham and a senior author of the meta-analysis study.

Mental Health Mission Midlands Translational Centre

A research initiative led by the University of Birmingham aimed at accelerating the development and delivery of innovative, evidence-based interventions to improve mental health outcomes and reduce disparities in care.

Birmingham Clinic for Advanced Mood Disorder Management (CALM)

A clinic involved in the research effort, delivering innovative treatments such as ketamine and neuromodulation to individuals with severe or treatment-resistant depression.

Got photos? Submit your photos here. ›

What they’re saying

“Depression is a debilitating illness, made even more so by the fact that antidepressants make no meaningful difference for almost half of all patients diagnosed with it. There is a growing body of research on repurposing treatments from other clinical domains to alleviate low mood. This study brings together the best possible evidence indicating that nitrous oxide has the potential to provide swift and clinically significant short-term improvements in patients with severe depression.”

— Kiranpreet Gill, PhD researcher, University of Birmingham

“This is a significant milestone in understanding the potential of nitrous oxide as an added treatment option for patients with depression who have been failed by current treatments. This population has often lost hope of recovery, making the results of this study particularly exciting. These findings highlight the urgent need for new treatments that can complement existing care pathways, and further evidence is needed to understand how this approach can best support people living with severe depression.”

— Steven Marwaha, Professor, University of Birmingham

What’s next

The team is now planning the first NHS trial in the UK to evaluate the safety and acceptability of nitrous oxide as a treatment for major depression. The results will be crucial in determining how nitrous oxide could be incorporated into NHS care and potentially expand the range of options available for patients who haven't responded to standard treatments.

The takeaway

The discovery that nitrous oxide, a commonly used pain reliever, could provide swift mood improvements for those struggling with severe, treatment-resistant depression offers a promising new avenue for addressing this debilitating mental health challenge. While more research is needed to determine the optimal dosing, long-term safety, and best integration into existing care pathways, these findings represent an exciting breakthrough in the search for innovative solutions to help the nearly half of depression patients who do not respond to traditional antidepressants.